Gufic BioSciences
361.40
+2.45(+0.68%)
Market Cap₹3,624.03 Cr
PE Ratio60.26
IndustryHealthcare
Company Performance:
1D+0.68%
1M+7.13%
6M-6.23%
1Y-12.79%
5Y+207.18%
View Company Insightsright
Latest news about Gufic BioSciences
Gufic Biosciences Reports Q1 Results: Revenue Up, Profit Down Amid Rising Costs Aug 13, 2025
Gufic BioSciences, an Indian pharmaceutical company, released its Q1 financial results. Consolidated revenue increased by 10.3% to ₹223.72 crore, up from ₹202.81 crore in the previous year. However, net profit declined by 37.3% to ₹13.07 crore from ₹20.86 crore. EBITDA decreased by 9.8% to ₹32.30 crore, with the EBITDA margin falling by 339 basis points to 14.25%. The company faced increased material costs, higher employee benefits expenses, and doubled finance costs. Gufic BioSciences continues to operate solely in the pharmaceuticals segment.
Gufic Biosciences Reports Mixed Q4 Results: Revenue Up, Profits Down May 30, 2025